The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

Evolutionary biologists have long hypothesized that the short-term physiological responses to stress help animals survive in ...

Jefferies analyst Roger Song confirmed a Buy rating and a price target of $8.00 for IO Biotech (NASDAQ:IOBT) shares. The ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Agenus (AGEN) presented multiple posters and presentations for botensilimab and balstilimab across various treatment lines of colon and ...

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

In collaboration with colleagues from international partner institutions, researchers at the University of Cologne have ...

The regulatory agency will review MSD’s new drug application (NDA) for Welireg under a Priority Review, with a Prescription ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.